Glanzmann thrombasthenia: A review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models

Blood

Volumn 118, Issue 23, 2011, Pages 5996-6005

  Nurden, Alan T ^a   Fiore, Mathieu ^a   Nurden, Paquita ^a   Pillois, Xavier ^a  

^a Ctr Geriatrie Ctr Hosp Univ B   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7; FIBRIN; FIBRINOGEN RECEPTOR; PROTEIN ITGA2B; PROTEIN ITGB3; RECOMBINANT BLOOD CLOTTING FACTOR 7; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

BLEEDING; BONE DISEASE; BRAIN DISEASE; CARDIOVASCULAR DISEASE; CYTOPLASM; DEEP VEIN THROMBOSIS; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; GLANZMANN DISEASE; HUMAN; LEUKOCYTE ADHESION DEFICIENCY; NEOPLASM; NONHUMAN; PHENOTYPE; PREGNANCY DISORDER; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; TISSUE DISTRIBUTION;

EID: 82955207656     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-07-365635     Document Type: Review

References (104)

1. George JN, Caen JP, Nurden AT. Glanzmann's thrombasthenia: the spectrum of clinical disease. Blood. 1990;75(7):1383-1395. (Pubitemid 20114873)
2. Nurden AT, George JN. Inherited abnormalities of the platelet membrane: Glanzmann thrombasthenia, Bernard-Soulier syndrome, and other disorders. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber S, eds. Hemostasis and Thrombosis (4th ed). Philadelphia, PA: Lippincott, Williams & Wilkins; 2006:987-1010.
3. Coller BS, Shattil SJ. The GPIIb/IIIa (integrin alphaIIbß3) odyssey: a technology-driven saga of a receptor with twists and turns and even a bend. Blood. 2008;112(8):3011-3025.
4. Xiao T, Takagi J, Coller BS,Wang JH, Springer TA. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature. 2004;432:59-67. (Pubitemid 39490825)
5. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110(6):673-687. (Pubitemid 35283958)
6. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10(1):9-22.
7. Bolton-Maggs PHB, Chalmers EA, Collins PW, et al. A review of platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol. 2006;135(5):603-633. (Pubitemid 44674072)
8. Morgan EA, Schneider JG, Baroni TE, et al. Dissection of platelet and myeloid cell defects by conditional targeting of the beta3-integrin subunit. FASEB J. 2010;24(4):1117-1127.
9. Nurden AT. Glanzmann thrombasthenia. Orphanet J Rare Dis. 2006;1:10-18.
10. Coller BS, Cheresh DA, Asch E, Seligsohn U. Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab patients with Glanzmann's thrombasthenia in Israel. Blood. 1991;77(1):75-83.
11. Emambokus NR, Frampton J. The glycoprotein IIb molecule is expressed on early murine hematopoietic progenitors and regulates their numbers in sites of hematopoiesis. Immunity. 2003;19(1):33-45. (Pubitemid 36859899)
12. Mitchell WB, Li JH, French DL, Coller BS. alphaIIbbeta3 biogenesis is controlled by engagement of alphaIIb in the calnexin cycle via the N15-linked glycan. Blood. 2006;107(7):2713-2719.
13. Wilcox DA, Wautier JL, Pidard D, Newman PJ. A single amino acid substitution flanking the fourth calcium binding domain of alphaIIb prevents maturation of the alphaIIbbeta3 integrin complex. J Biol Chem. 1994;269(6):4450-4457.
14. Nelson EJR, Li J, Mitchell WN, Chandy M, Srivastava A, Coller BS. Three novel beta-propeller mutations causing Glanzmann thrombasthenia result in production of normally stable pro-alphaIIb but variably impaired progression of pro-alphaIIbbeta3 from endoplasmic reticulum to Golgi. J Thromb Haemost. 2005;3(12):2773-2783. (Pubitemid 41819807)
15. Gonzalez-Manchon C, Arias-Salgado EG, Butta N, et al. A novel homozygous splice junction mutation in GPIIb associated with alternative splicing, nonsense-mediated decay of GPIIbmRNA, and type II Glanzmann's thrombasthenia. J Thromb Haemost. 2003;1(5):1071-1078.
16. Mansour W, Einav Y, Hauschner H, Koren A, Seligsohn U, Rosenberg N. An alphaIIb mutation in patients with Glanzmann thrombasthenia located in the N-terminus of blade 1 of the beta-propeller (Asn2Asp) disrupts a calcium binding site in blade 6. J Thromb Haemost. 2011;9(1):192-200.
17. D'Andrea G, Colaizzo D, Vecchione G, et al. Glanzmann's thrombasthenia: identification of 19 new mutations in 30 patients. Thromb Haemost. 2002;87(6):1034-1042. (Pubitemid 34624887)
18. Peretz H, Rosenberg N, Landau M, et al. Molecular diversity of Glanzmann thrombasthenia in Southern India: new insights into mRNA splicing and structure-function correlations of alphaIIbbeta3 integrin (ITGA2B, ITGB3). Hum Mutat. 2006;27(4):359-369.
19. Kannan M,Ahmad F, Yadav B, Kumar R, Choudry VP, Saxena R. Molecular defects in ITGA2B and ITGB3 genes in patients with Glanzmann's thrombasthenia. J Thromb Haemost. 2009;7(11):1878-1885.
20. Nurden P, Poujol C, Durrieu-Jais C, et al. Labelling of the internal pool of GPIIb-IIIa in platelets by c7E3 Fab fragments: flow and endocytic mechanisms contribute to the transport. Blood. 1999;93(5):1622-1633. (Pubitemid 29102490)
21. Chen P, Melchior C, Brons NHC, Schlegel N, Caen J, Kieffer N. Probing conformation changes in the I-like domain and the cysteine-rich repeat of human beta3 integrins following disulfide bond disruption by cysteine mutations. J Biol Chem. 2001;276(42):38628-38635.
22. Hainaud P, Brouland J-P, André P, et al. Dissociation between fibrinogen and fibrin interaction with platelets in patients with different subtypes of Glanzmann's thrombasthenia: studies in an ex vivo perfusion chamber model. Br J Haematol. 2002;119(4):998-1004. (Pubitemid 35469170)
23. Newman PJ, Seligsohn U, Lyman S, Coller BS. The molecular genetic basis of Glanzmann thrombasthenia in the Iraqi-Jewish and Arab populations in Israel. Proc Natl Acad Sci U S A. 1991;88(8):3160-3164. (Pubitemid 21916579)
24. Coller BS, Seligsohn U, West SM, Scudder LE, Norton KJ. Platelet fibrinogen and vitronectin in Glanzmann thrombasthenia: evidence consistent with specific roles for glycoprotein IIb/IIIa and alphavbeta3 integrins in platelet protein trafficking. Blood. 1991;78(10):2603-2610.
25. Poujol C, Nurden AT, Nurden P. Ultrastructural analysis of the distribution of the vitronectin receptor (alphavbeta3) in human platelets and megakaryocytes reveals an intracellular pool and labelling of the alpha-granule membrane. Br J Haematol. 1997;96(4):823-835. (Pubitemid 27115880)
26. Coller BS, Seligsohn U, Peretz H, Newman PJ. Glanzmann thrombasthenia: new insights from an historical perspective. Semin Hematol. 1994;31(4):301-311. (Pubitemid 24325182)
27. Tadokoro S, Tomiyama Y, Honda S, et al. Missense mutations in the beta3 subunit have a different impact on the expression and function between alphaIIbbeta3 and alphavbeta3. Blood. 2002;99(3):931-938.
28. Morel-Kopp M-C, Melchior C, Chen P, et al. A naturally occurring point mutation in the beta3 integrin MIDAS-like domain affects differently alphavbeta3 and alphaIIbbeta3 receptor function. Thromb Haemost. 2001;86(6):1425-1434. (Pubitemid 34007515)
29. Hauschner H, Landau M, Seligsohn U, Rosenberg N. A unique interaction between alphaIIb and beta3 in the head region is essential for outside-in signaling-related functions of alphaIIbbeta3 integrin. Blood. 2010;115(22):4542-4550.
30. Ginsberg MH, Frelinger AL, Lam SC-T, et al. Analysis of platelet aggregation disorders based on flow cytometric analysis of membrane glycoprotein IIb-IIIa with conformation-specific monoclonal antibodies. Blood. 1990;76(10):2017-2023.
31. Loftus JC, O'Toole TE, Plow EF, Glass A, Frelinger AL 3rd, Ginsberg MH. A beta3 mutation abolishes ligand binding and alters divalent cation-dependent conformation. Science. 1990;249(4971):915-918.
32. Bajt ML, Loftus JC. Mutation of a ligand binding domain of beta3 integrin: integral role of oxygenated residues in alphaIIbbeta3 (GPIIb-IIIa) receptor function. J Biol Chem. 1994;269(33):20913-20919.
33. Nurden AT, Rosa J-P, Fournier D, et al. A variant of Glanzmann's thrombasthenia with abnormal glycoprotein IIb-IIIa complexes in the platelet membrane. J Clin Invest. 1987;79:962-969. (Pubitemid 17050925)
34. Bajt ML, Ginsberg MH, Frelinger AL, Berndt MC, Loftus JC. A spontaneous mutation of integrin alphaIIbbeta3 (platelet glycoprotein IIb-IIIa) helps define a ligand binding site. J Biol Chem. 1992;267(6):3789-3794.
35. 214Trp mutation. J Clin Invest. 1992;89(6):1995-2004.
36. Springer TA, Zhu J, Xiao T. Structural basis for distinctive recognition of fibrinogen gammaC peptide by the platelet integrin alphaIIbbeta3. J Cell Biol. 2008;182(4):791-800.
37. Raborn J, Wang W, Luo B-H. Regulation of integrin alphaIIbbeta3 ligand binding and signaling by the metal ion binding sites in the beta1 domain. Biochemistry. 2011;50:2084-2091.
38. Jackson DE, White MM, Jennings LK, Newman PJ. A Ser162->Leu mutation within glycoprotein (GP)IIIa (integrin beta3) results in an unstable alphaIIbbeta3 complex that retains partial function in a novel form of type II Glanzmann thrombasthenia. Thromb Haemost. 1998;80(1):42-48. (Pubitemid 28353496)
39. .Ward CM, Kestin AS, Newman PJ. A Leu262Pro mutation in the integrin beta3 subunit results in an alphaIIbbeta3 complex that binds fibrin but not fibrinogen. Blood. 2000;96(1):161-169. (Pubitemid 30456466)
40. Nair S, Ghosh K, Shetty S, Mohanty D. A novel Ser123Pro substitution in the MIDAS domain of integrin beta3 associated with variant Glanzmann's thrombasthenia in an Indian patient. Haematologica. 2004;89(12):1529-1530. (Pubitemid 39643524)
41. Chen Y-P, Djaffar I, Pidard D, et al. Ser-752->Pro mutation in the cytoplasmic domain of integrin beta3 subunit and defective activation of platelet integrin alphaIIbbeta3 (glycoprotein IIb-IIIa) in a variant of Glanzmann thrombasthenia. Proc Natl Acad Sci U S A. 1992;89(21):10169-10173.
42. Nurden P, Poujol C, Winckler J, Combrie R, Caen JP, Nurden AT. A Ser752->Pro substitution in the cytoplasmic domain of beta3 in a Glanzmann thrombasthenia variant fails to prevent interactions between the alphaIIbbeta3 integrin and the platelet granule pool of fibrinogen. Br J Haematol. 2002;118(4):1143-1151. (Pubitemid 35025983)
43. 752->P) impairs bidirectional signaling through alphaIIbß3 (platelet glycoprotein IIb-IIIa). Blood. 1994;84(6):1857-1865.
44. Tahiliani PD, Singh L, Auer KL, LaFlamme SE. The role of conserved amino acid motifs within the integrin beta3 cytoplasmic domain in triggering focal adhesion kinase phosphorylation. J Biol Chem. 1997;272(12):7892-7898. (Pubitemid 27137349)
45. Kieffer N, Melchior C, Guinet JM, Michels S, Gouon V, Bron N. Serine 752 in the cytoplasmic domain of the beta3 integrin subunit is not required for alphavbeta3 postreceptor signaling events. Cell Adhes Commun. 1996;4(1):25-39. (Pubitemid 26325330)
46. Moser M, Nieswandt B, Ussar S, Pozgajova M, Fassler R. Kindlin-3 is essential for integrin activation and platelet aggregation. Nat Med. 2008;14(3):325-330. (Pubitemid 351347914)
47. .Wang R, Shattil SJ, Ambruso DR, Newman PJ. Truncation of the cytoplasmic domain of beta3 in a variant form of Glanzmann thrombasthenia abrogates signaling through the integrin alphaIIbbeta3 complex. J Clin Invest. 1997;100(9):2393-2403. (Pubitemid 27500165)
48. Boylan B, Gao C, Rathore V, Gill JC, Newman DK, Newman PJ. Identification of FcγRIIa as the ITAM-bearing receptor mediating alphaIIbbeta3 outside-in integrin signaling in human platelets. Blood. 2008;112(7):2780-2786.
49. Arias-Salgado EG, Butta N, Gonzalez-Manchon C, Larrucea S, Ayuso MS, Parrilla R. Competition between normal (674C) and mutant (674R) subunits: role of the molecular chaperone BiP in the processing of GPIIb-IIIa complexes. Blood. 2001;97(9):2640-2647.
50. Honda S, Tomiyama Y, Shiraga M, et al. A twoamino acid insertion in the Cys146-Cys167 loop of the alphaIIb subunit is associated with a variant of Glanzmann thrombasthenia. J Clin Invest. 1998;102(6):1183-1192. (Pubitemid 28436278)
51. Kiyoi T, Tomiyama Y, Honda S, et al. A naturally occurring Tyr143His alphaIIb mutation abolishes alphaIIbbeta3 function for soluble ligands but retains its ability for mediating cell adhesion and clot retraction: comparison with other mutations causing ligand-binding defects. Blood. 2003;101(9):3485- 3491. (Pubitemid 36857931)
52. .Westrup D, Santoso S, Follert-Hagenorff K, et al. Glanzmann thrombasthenia Frankfurt I is associated with a point mutation Thr176Ile in the Nterminal region of alphaIIb subunit integrin. Thromb Haemost. 2004;92(5):1040-1051. (Pubitemid 39545528)
53. Kashiwagi H, Tomiyama Y, Tadokoro S, et al. A mutation in the extracellular cysteine-rich repeat region of the beta3 subunit activates integrins alphaIIbbeta3 and alphavbeta3. Blood. 1999;93(8):2559-2568. (Pubitemid 29181188)
54. Vanhoorelbeke K, De Meyer SF, Pareyn SF, et al. The novel S527F mutation in the integrin beta3 chain induces a high affinity alphaIIbbeta3 receptor by hindering adoption of the bent conformation. J Biol Chem. 2009;284(22):14914- 14920.
55. Kamata T, Ambo H, Puzon-McLaughlin W, et al. Critical cysteine residues for regulation of integrin alphaIIbbeta3 are clustered in the epidermal growth factor domains of the beta3 subunit. Biochem J. 2004;378(3):1079-1082. (Pubitemid 38406889)
56. Mor-Cohen R, Rosenberg N, Peretz H, et al. Disulfide bond disruption by a beta3-Cys549Arg mutation in six Jordanian families with Glanzmann thrombasthenia causes diminished production of constitutively active alphaIIbbeta3. Thromb Haemost. 2007;98(6):1257-1265. (Pubitemid 350239098)
57. Ruiz C, Liu CY, Sun QH, et al. A point mutation in the cysteine-rich domain of glycoprotein (GP) IIIa results in the expression of a GPIIb-IIIa (alphaIIbbeta3) integrin locked in a high affinity state and a Glanzmann thrombasthenia-like phenotype. Blood. 2001;98(8):2432-2441.
58. Wilcox DA, Fang J, North P, Nurden P, Nurden AT, Valentin N. High mortality in mice with platelets expressing integrin alphaIIbbeta3 locked in its high affinity state [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;112:1832.
59. Gonzalez-Manchon C, Butta N, Larrucea S, et al. A variant thrombasthenic phenotype associated with compound heterozygosity of integrin beta3-subunit: (Met124Val)beta3 alters the subunit dimerization rendering a decreased number of constitutive active alphaIIbbeta3 receptors. Thromb Haemost. 2004;92(6):1377-1386. (Pubitemid 39642550)
60. Hardisty R, Pidard D, Cox A, et al. A defect of platelet aggregation associated with an abnormal distribution of glycoprotein IIb-IIIa complexes within the platelet: the cause of a lifelong bleeding disorder. Blood. 1992;80(3):696-708.
61. Peyruchaud O, Nurden AT, Milet S, et al. R to Q substitution in the GFFKR sequence of the cytoplasmic domain of the integrin alphaIIb subunit in a patient with a Glanzmann's thrombasthenia-like syndrome. Blood. 1998;92(11):4178-4187. (Pubitemid 28544333)
62. Nurden AT, Pillois X, Fiore M, Heilig R, Nurden P. Glanzmann thrombasthenia-like syndromes associated with macrothrombocytopenias and mutations in the genes encoding the alphaIIbbeta3 integrin. Semin Thromb Hemost. 2011;37(6):698-706.
63. Kunishima S, Kashiwagi H, Otsu M, et al. Heterozygous ITGA2B R995W mutation inducing constitutive activation of the alphaIIbbeta3 receptor affects proplatelet formation and causes congenital macrothrombocytopenia. Blood. 2011;117(20):5479-5484.
64. Yang J, Ma YQ, Page RC, Misra S, Plow EF, Qin J. Structure of an integrin alphaIIbbeta3 transmembrane-cytoplasmic heterocomplex provides insight into integrin activation. Proc Natl Acad Sci U S A. 2009;106(42):17729-17734.
65. Ghevaert C, Salamann A, Watkins NA, et al. A nonsynonymous SNP in the ITGB3 gene disrupts the conserved membrane proximal cytoplasmic salt bridge in the alphaIIbbeta3 integrin and cosegregates dominantly with abnormal proplatelet formation and macrothrombocytopenia. Blood. 2008;111(7):3407-3414.
66. Gresele P, Falcinelli E, Giannini S, et al. Dominant inheritance of a novel integrin beta3 mutation associated with a hereditary macrothrombocytopenia and platelet dysfunction in two Italian families. Haematologica. 2009;94(5):663-669.
67. Jayo A, Conde I, Lastres P, et al. L1718P mutation in the membrane-proximal cytoplasmic tail of beta3 promotes abnormal alphaIIbbeta3 clustering and lipid domain coalescence, and associates with a thrombasthenia-like phenotype. Haematologica. 2010;95(7):1158-1166.
68. McDowall A, Inwald D, Leitinger B, et al.Anovel form of integrin dysfunction involving beta1, beta2 and beta3 integrins. J Clin Invest. 2003;111(1):51-60. (Pubitemid 36134848)
69. Kuijpers TW, van Bruggen R, Kamerbeek N, et al. Natural history and early diagnosis of LAD-1/variant syndrome. Blood. 2007;109(8):3529-3537. (Pubitemid 46572546)
70. Crittenden JR, Bergmeier W, Zhang Y, et al. CalDAG-GEFI integrates signaling for platelet aggregation and thrombus formation. Nat Med. 2004;10(9):982-986. (Pubitemid 39273740)
71. KuijpersTW, van de Vijver E,Weterman MAJ, et al. LAD-1/variant syndrome is caused by mutations in FERMT3. Blood. 2009;113(19):4740-4746.
72. Svensson L, Howarth K, McDowall A, et al. Leukocyte adhesion deficiency-III is caused by mutations in KINDLIN3 affecting integrin activation. Nat Med. 2009;15(3):306-312.
73. Malinin BL, Plow EF, Byzova TV. Kindlins in FERM adhesion. Blood. 2010;115(20):4011-4017.
74. McDowall A, Svensson L, Stanley P, et al. Two mutations in the kindlin3 gene of a new leukocyte adhesion deficiency III patient reveal distinct effects on leukocyte function in vitro. Blood. 2010;115(23):4834-4842.
75. Bialkowska K, Ma Y-Q, Bledzka K, et al. The integrin co-activator kindlin-3 is expressed and functional in a non-hematopoietic cell, the endothelial cell. J Biol Chem. 2010;285(24):18640-18649.
76. D'Andrea G, Margaglione M. Glanzmann's Thrombasthenia Italian Team (GLATIT). Glanzmann's thrombasthenia: modulation of clinical phenotype by alpha2C807T gene polymorphism. Haematologica. 2003;88(12):1378-1382. (Pubitemid 38029721)
77. ten Cate H, Brandjes DPM, Smits PHM, Van Mourik JA. The role of platelets in venous thrombosis: a patient with Glanzmann's thrombasthenia and factor V Leiden mutation suffering from deep vein thrombosis. J Thromb Haemost. 2003;1(2):394-395.
78. Ghosh K, Kulkarni B, Nair S, Shetty S, Mohanty D. Human platelet alloantigen polymorphism in Glanzmann's thrombasthenia and its impact on the severity of the disease. Br J Haematol. 2002;119(2):348-353. (Pubitemid 35365480)
79. Jacquelin B, Tuleja E, Kunicki TJ, Nurden P, Nurden AT. Analysis of platelet membrane glycoprotein polymorphisms in Glanzmann thrombasthenia showed the French gypsy mutation in the alphaIIb gene to be strongly linked to the HPA-1b polymorphism in beta3. J Thromb Haemost. 2003;1(3):573-575.
80. Kunicki TJ, Nugent DJ. The genetics of normal platelet reactivity. Blood. 2010;116(15):2627-2634.
81. Erpenbeck L, Schön MP. Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. Blood. 2010;115(17):3427-3436.
82. Furman MI, Krueger LA, Linden MD, Barnard MR, Frelinger AL 3rd, Michelson AD. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J Am Coll Cardiol. 2004;43(12):2319-2325. (Pubitemid 38757605)
83. Gerold G, Ajaz KA, Bienert M, Laws H-J, Zychlinsky A, L de Diego JL.Atoll-like receptor 2-integrin beta3 complex senses bacterial lipopeptides via vitronectin. Nat Immunol. 2008;9(7):761-768. (Pubitemid 351859159)
84. Toogeh G, Sharifian R, Lak M, Safeea R, Artoni A, Peyvandi F. Presentation and patterns of symptoms in 382 patients with Glanzmann thrombasthenia in Iran. Am J Hematol. 2004;77(2):198-199. (Pubitemid 39281870)
85. Hodivala-Dilke KM, McHugh KP, Tsakiris DA, et al. beta3-Integrin- deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest. 1999;103(2):229-238. (Pubitemid 29053141)
86. Reynolds LE, Wyder L, Lively JC, et al. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med. 2002;8(1):27-34. (Pubitemid 34101725)
87. Reynolds AR, Reynolds LE, Nagel TE, et al. Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in beta3-integrin-deficient mice. Cancer Res. 2004;64(23):8343-8350.
88. Robinson SD, Reynolds LE, Wyder L, Hicklin DJ, Hodivala-Dilke KM. Beta3-integrin regulates vascular endothelial growth factor-A-dependent permeability. Arterioscler Thromb Vasc Biol. 2004;24(11):2108-2114. (Pubitemid 39482438)
89. .Weis SM, Lindquist JN, Barnes LA, et al. Cooperation between VEGF and beta3 integrin during cardiac vascular development. Blood. 2007;109(5):1962- 1970. (Pubitemid 46348193)
90. Ren J, Avery J, Zhao H, Schneider JG, Ross FP, Muslin AJ. Beta3integrin deficiency promotes cardiac hypertrophy and inflammation. J Mol Cell Cardiol. 2007;42(2):367-377. (Pubitemid 46135609)
91. Schneider JG, Zhu Y, Coleman T, Semenkovich CF. Macrophage beta3 integrin suppresses hyperlipidemia-induced inflammation by modulating TNFalpha expression. Arterioscler Thromb Vasc Biol. 2007;27(12):2699-2706. (Pubitemid 350158925)
92. .Weng S, Zemany L, Standley KN, et al. Beta3 integrin deficiency promotes atherosclerosis and pulmonary inflammation in high-fat-fed hyperlipidemic mice. Proc Natl Acad Sci U S A. 2003; 100(11):6730-6735. (Pubitemid 36666648)
93. Reynolds LE, Conti FJ, Lucas M, et al. Accelerated re-epithelialization in beta3-integrin-deficient mice is associated with enhanced TGF-betal signaling. Nat Med. 2005;11(2):167-174. (Pubitemid 40321352)
94. McHugh KP, Hodivala-Dilke K, Zheng MH, et al. Mice lacking β3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest. 2000;105(4):433-440. (Pubitemid 30127243)
95. Feng X, Novack DV, Faccio R, et al. A Glanzmann's mutation in beta3 integrin specifically impairs osteoclast function. J Clin Invest. 2001;107(9):1137-1144. (Pubitemid 32422910)
96. Bakewell SJ, Nestor P, Prasad S, et al. Platelet and osteoclast beta3 integrins are critical for bone metastasis. Proc Natl Acad Sci U S A. 2003;100(24):14205-14210. (Pubitemid 37499215)
97. Karpatkin S, Pearlstein E, Ambrogio C, Coller BS. Role of adhesive proteins in platelet tumour interaction in vitro and metastasis formation in vivo. J Clin Invest. 1988;81(4):1012-1019.
98. Taverna D, Moher H, Crowley D, Borsig L, Varki A, Hynes RG. Increased primary tumour growth in mice null for beta3- or beta3/beta5 integrins or selectins. Proc Natl Acad Sci U S A. 2004;101(3):763-768. (Pubitemid 38121032)
99. Schmidt S, Nakchbandi I, Ruppert R, et al. Kindlin-3-mediated signaling from multiple integrin classes is required for osteoclast-mediated bone resorption. J Cell Biol. 2011;192(5):883-897.
100. Carter MD, Shah CR, Muller CL, Crawley JN, Carneiro AM, Veenstra-VanderWeele J. Absence of preference for social novelty and increased grooming in integrin beta3 knockout mice: initial studies and future directions. Autism Res. 2011;4:(1):57-67.
101. Tronik-Le Roux D, Roullot V, Poujol C, Kortulewski T, Nurden P, Marguérie G. Thrombasthenic mice generated by replacement of the integrin alphaIIb gene: demonstration that transcriptional activation of this megakaryocytic locus precedes lineage commitment. Blood. 2000;96(4):1399-1408. (Pubitemid 30658470)
102. Berlanga O, Emambokus N, Frampton J. GPIIb (CD41) integrin is expressed on mast cells and influences their adhesion properties. Exp Hematol. 2005;33(4):403-412. (Pubitemid 40387622)
103. Brill A, Fuchs TA, Chauhan AK, et al. von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood. 2011;117(4):1400-1407.
104. Baker NA, Sept D, Joseph S, Holst MJ, McCammon JA. Electrostatics of nanosystems: application to microtubules and the ribosome. Proc Natl Acad Sci U S A. 2001;98(18):10037-10041. (Pubitemid 32802969)